BR112022019649A2 - Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19 - Google Patents

Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19

Info

Publication number
BR112022019649A2
BR112022019649A2 BR112022019649A BR112022019649A BR112022019649A2 BR 112022019649 A2 BR112022019649 A2 BR 112022019649A2 BR 112022019649 A BR112022019649 A BR 112022019649A BR 112022019649 A BR112022019649 A BR 112022019649A BR 112022019649 A2 BR112022019649 A2 BR 112022019649A2
Authority
BR
Brazil
Prior art keywords
covid
cov
sars
formulations
proteins
Prior art date
Application number
BR112022019649A
Other languages
English (en)
Portuguese (pt)
Inventor
Shreema Merchant Dr
PATEL Manit
Elaine Duncan Robin
Vishal Anant Jadhav Dr
Fernanda De Andrade Fernandes Maria
Original Assignee
Akseera Pharma Corp
Shreema Merchant Dr
PATEL Manit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseera Pharma Corp, Shreema Merchant Dr, PATEL Manit filed Critical Akseera Pharma Corp
Publication of BR112022019649A2 publication Critical patent/BR112022019649A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022019649A 2020-03-29 2021-03-30 Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19 BR112022019649A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN202021013770 2020-03-29
IN202021030633 2020-07-18
IN202021054151 2020-12-12
PCT/IN2021/050325 WO2021199078A2 (en) 2020-03-29 2021-03-30 Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19.

Publications (1)

Publication Number Publication Date
BR112022019649A2 true BR112022019649A2 (pt) 2022-12-27

Family

ID=77927896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019649A BR112022019649A2 (pt) 2020-03-29 2021-03-30 Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19

Country Status (9)

Country Link
US (1) US20240226120A1 (https=)
EP (1) EP4126913A4 (https=)
JP (1) JP2023528561A (https=)
CN (1) CN115968375A (https=)
AU (1) AU2021247269A1 (https=)
BR (1) BR112022019649A2 (https=)
IL (1) IL296892A (https=)
MX (1) MX2022012165A (https=)
WO (1) WO2021199078A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
CN115531315B (zh) * 2022-12-05 2023-04-07 上海惠盾因泰生物科技有限公司 重组人干扰素λ1鼻喷雾剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
NL2009671C2 (en) * 2012-10-19 2014-04-23 Fytagoras B V New antiviral use for acidic cannabinoids.
WO2017011785A1 (en) * 2015-07-15 2017-01-19 National Concessions Group Inc. Topical antiviral formulations and methods of using the same
WO2020257588A1 (en) * 2019-06-20 2020-12-24 Shaman Naturals, Llc Compositions for preventing and treating viral infections
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
US11338010B2 (en) * 2020-03-30 2022-05-24 Suzhou Kintor Pharmaceuticals, Inc. Systems, methods, and kits for diagnostics and treatment of viral respiratory infection
US20230181484A1 (en) * 2020-05-11 2023-06-15 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
US20230338396A1 (en) * 2020-05-14 2023-10-26 Augusta University Research Institute, Inc. Cannabidiol as a therapeutic modality for covid-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Also Published As

Publication number Publication date
WO2021199078A3 (en) 2021-12-09
US20240226120A1 (en) 2024-07-11
WO2021199078A2 (en) 2021-10-07
MX2022012165A (es) 2023-01-24
CN115968375A (zh) 2023-04-14
JP2023528561A (ja) 2023-07-05
AU2021247269A1 (en) 2022-12-01
EP4126913A4 (en) 2024-09-18
IL296892A (en) 2022-12-01
EP4126913A2 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
BR112022019649A2 (pt) Interação das proteínas sars-cov-2 com mecanismos moleculares e celulares de células hospedeiras e formulações para tratar o covid-19
Hodge Osteopathic lymphatic pump techniques to enhance immunity and treat pneumonia
BR112021022283A2 (pt) Novas endolisinas de gardnerella e usos das mesmas
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
EP4477267A3 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
RU2668827C2 (ru) Топическая противомикробная дерматологическая композиция
CO2022015966A2 (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
Gürel et al. Can parasites be useful?
Singh et al. Leg ulceration in sickle cell disease: an early and visible sign of end-organ disease
BR112023024701A2 (pt) Métodos de tratamento de doenças do fígado
CL2025001428A1 (es) Composiciones farmacéuticas para administración ocular
Avijgan et al. Aloe vera gel as a traditional and complementary method for chronic skin burn: A case report
BR112017022390A2 (pt) composição farmacêutica
CO2023014650A2 (es) Dosificación y administración de l-asparaginasa recombinante
BR112015013215A2 (pt) proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares
BR112022027124A2 (pt) Formulações para promover a hidratação e métodos de uso das mesmas
CN110876740B (zh) volvalerenal K在修复皮肤破损中的用途
BR112022004949A2 (pt) Composição farmacêutica contendo antibióticos para cura de infecções bacterianas e ferimentos
BR112022020350A2 (pt) Proteína de fusão recombinante para prevenir ou tratar doenças fibróticas
CN103341036B (zh) 一种治疗烧伤的外用药物
Tulupov et al. Features of medical assistance to victims with combined traumas caused by road accidents in Saint-Petersburg
KR20250069681A (ko) 피부 및 경피 섬유화 질환, 장애, 및 관련 통증 및 염증의 병용 치료
Kucharzewski et al. Research Article Topical Treatment of Nonhealing Venous Leg Ulcer with Propolis Ointment
BR102023019114A2 (pt) INJETÁVEL RESISTENTE PARA COMBATE A FlBROSE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.